HomepageGRFS • NASDAQ
add
Grifols
$Â 9,00
Na sluitingstijd:(0,00%)0,00
$Â 9,00
Gesloten: 8 jul, 16:01:46 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 8,87
Dag-range
$Â 8,95 - $Â 9,13
Jaar-range
$Â 6,19 - $Â 9,96
Beurswaarde
7,72Â mld. USD
Gem. volume
633,26K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,79Â mld. | 9,85% |
Bedrijfskosten | 411,42Â mln. | 1,21% |
Netto inkomsten | 59,72Â mln. | 178,84% |
Netto winstmarge | 3,34 | 153,03% |
Winst per aandeel | — | — |
EBITDA | 404,97Â mln. | 16,53% |
Effectief belastingtarief | 19,82% | — |
Balans
Totale activa
Totale passiva
(EUR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 1,01Â mld. | 65,18% |
Totale activa | 20,98Â mld. | -4,44% |
Totale passiva | 12,68Â mld. | -8,29% |
Totaal aandelenvermogen | 8,29 mld. | — |
Uitstaande aandelen | 680,41 mln. | — |
Koers-boekwaardeverhouding | 1,07 | — |
Rendement op activa | 3,46% | — |
Rendement op kapitaal | 3,96% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 59,72Â mln. | 178,84% |
Operationele kasstroom | 135,47Â mln. | 182,14% |
Kasstroom uit beleggingen | -197,34Â mln. | -124,38% |
Kasstroom uit financiering | -133,65Â mln. | -180,78% |
Nettomutatie in liquide middelen | -226,96Â mln. | -180,09% |
Vrije kasstroom | 227,79Â mln. | 189,52% |
Over
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Opgericht
18 nov 1940
Website
Werknemers
23.800